Indication: RSV bronchiolitis

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 36 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)

Sub-indication: RSV

Study Type: Drug Study

Principal Investigator: Kristina Bryant, M.D.
Norton Children's Infectious Diseases, affiliated with the UofL School of Medicine

Sponsor: Sponsor: Enanta Pharmaceuticals, Inc.

Search our entire site.